Reading Scientific Services Ltd (RSSL) has been named Employer of the Year 2021 at the Thames Valley Awards, in recognition of its outstanding dedication to staff development, engagement and wellbeing.
RSSL successfully demonstrated its commitment to employees through a diverse, inclusive and creative programme of initiatives. Importantly, the organisation also showed its ability to adapt to the restrictions and pressures placed on staff during the pandemic; moving key aspects online and boosting other areas of support where they were needed most.
Commenting on the win, Jacinta George,…
Reading Scientific Services Ltd (RSSL) has been named Business of the Year 2021 at the Thames Valley Awards, with the judges praising its forward-thinking approach and strong commercial performance.
“We are delighted to receive this award, especially given the huge challenges of the last year. I am so proud of everyone at RSSL for continuing to deliver an exceptional level of service for our clients, while still supporting each other. This resilience, determination and strong sense of purpose has been instrumental in helping our business grow and emerge stronger than ever before,” said…
Research Triangle Park, NC, USA and Cambridge, UK, 5 May 2021 -- Inivata, a leader in liquid biopsy, today announces that NeoGenomics, Inc (NASDAQ: NEO.), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has agreed to acquire Inivata. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million.
Inivata, with its leading liquid biopsy technology platform, will remain a…
Cambridge, UK, 04 May 2021: Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million USD in this round. The funding will support the advancement of Mogrify’s immuno-oncology and ophthalmology programs, as well as continued platform development and the exploration of cell reprogramming for novel therapeutic application.
This second close of the Company’s…
AMSBIO has launched two new biotinylated formats of the 10E4 Heparan Sulfate antibody (high and low biotin) along with a starter pack to allow scientists to test both formats at a reduced cost.Heparan Sulfate (HS) is a highly sulfated linear polysaccharide that is attached to a core protein to form HS Proteoglycans on the cell membrane or in the extracellular matrix. It is involved in important biological processes due to it displaying specific interactions with many biologically active proteins. In particular, HS has emerged as a key factor in infection by the SARS-CoV-2 virus,…
Cleveland, UK, 29th April 2021 / Sciad Newswire / Leading UK peptide and antibody producers, Cambridge Research Biochemicals (CRB) have today signed a new distribution agreement with Fluoroprobes, LLC (FPL) and Click Chemistry Tools (CCT) to add FPL and CCT’s generic fluorescent activated dyes and click chemistry enabled click-reactive dyes to their existing service portfolio. The distribution agreement grants CRB the rights to market and sell the generic and improved Alexa Fluor-based DISCOVERY® Dyes both as part of their custom services, and with their catalogue peptide (DISCOVERY®…
Research Triangle Park, NC, USA, Cambridge, UK, Irvine, Calif., and Amsterdam – 28 April 2021 – Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision oncology for breast cancer.
Under the terms of the agreement, Agendia will gain co-exclusive rights to distribute Inivata’s RaDaR® liquid biopsy assay for the detection of Minimal Residual Disease (MRD) and early detection of relapse in patients with breast cancer in North America and Europe, with the option of extending territories over time. It is expected…
NOTTINGHAM, UK – 27 April, 2021 – Life Science Newswire – Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider, has established a new office presence in South San Francisco’s biotech hub at Oyster Point, where it can better serve current and future clients on the US west coast.The new office presence comes in the wake of another year of impressive growth for the company, which has recently expanded operations at its headquarters in Nottingham, UK, as well as opening a second co-located integrated drug discovery site at the world-class research…